About Anne-Marie Wills, MD, MPH

Anne-Marie Wills MD MPH is a Neurologist specializing in neurodegenerative disease, such as Parkinson's Disease, PSP, and ALS. She received her BA from Princeton University, her MD from Columbia College Physicians & Surgeons, and her MPH from Harvard School of Public Health. She completed her specialty training in the Partners Neurology residency program, a combined program between Massachusetts General Hospital and Brigham and Women's Hospital. She has been on staff at M.G.H. since 2006.

Dr. Wills' research focuses on environmental risk factors and determinants of neurodegenerative disease progression, including nutrition, caffeine and pesticides. Her multi-center clinical trial of nutrition in ALS (funded by the Muscular Dystrophy Association) showed that a calorically-dense diet was better tolerated and led to fewer adverse events, including deaths, than a standard diet (Wills et al. The Lancet, 2014).  She is also investigating the effects of exercise interventions for neurodegenerative diseases.

She is the director of the CurePSP Center of Care at MGH which provides multidisciplinary care for people with Progressive Supranuclear Palsy.  She is a member of the Movement Disorders Society, the Parkinson’s Study Group (PSG), the NorthEast ALS Consortium, and the American Academy of Neurology.  She is co-director of the Genes and Environment Working Group of the PSG, co-founder of the Atypical Parkinsonian Disorders working group of the PSG and is the PI of several clinical trials in Parkinson’s disease and PSP.

Departments, Centers, & Programs:

Clinical Interests:

Treats:

Languages:

Locations

Neurology & Stroke Services
15 Parkman Street
Boston, MA 02114-3117
617-726-5532
617-724-9234
Fax: 617-726-4101

Medical Education

  • MD, Columbia University College of Physicians and Surgeons
  • MPH, Harvard T. H. Chan School of Public Health
  • Residency, Brigham and Women's Hospital
  • Fellowship, Massachusetts General Hospital

American Board Certifications

  • Neurology, American Board of Psychiatry and Neurology

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Research

Dr. Wills' research focuses on environmental risk factors and determinants of neurodegenerative disease progression, including nutrition, caffeine and pesticides. Her multi-center clinical trial of nutrition in ALS (funded by the Muscular Dystrophy Association) showed that a calorically-dense diet was better tolerated and led to fewer adverse events, including deaths, than a standard diet (Wills et al. The Lancet, 2014).  She has shown that weight loss is associated with worse disease progression in Parkinson's disease (Wills et al. JAMA Neurology, 2016).  She is also the Principal Investigator of several Parkinson's Disease clinical trials testing exercise interventions in PD and the director of the MGH CurePSP Center of Care for Progressive Supranuclear Palsy.

High-calorie feeding may slow progression of ALS

Publications

  • View my most recent publications at PubMed

    Wills AM, Hubbard J, Mackline EA et al. Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial, The Lancet, 28 February 2014

    Wills AM, Pérez A, et. Association Between Change in Body Mass Index, Unified Parkinson's Disease Rating Scale Scores, and Survival Among Persons With Parkinson Disease. JAMA Neurol. 2016 Mar;73(3):321-8.

    Wills AM, Garry J, Hubbard J, Mezoian T, Breen CT, Ortiz-Miller C, Nalipinski P, Sullivan S, Berry JD, Cudkowicz M, Paganoni S, Chan J, Macklin EA. Nutritional counseling with or without mobile health technology: a randomized open-label standard-of-care-controlled trial in ALS. BMC Neurology. 2019 May 29;19(1):104. doi: 10.1186/s12883-019-1330-6.